Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Metagenomi, Inc. stock logo
MGX
Metagenomi
$1.38
+3.4%
$1.38
$1.24
$3.95
$51.73M0.64225,614 shs98,314 shs
Moderna, Inc. stock logo
MRNA
Moderna
$49.28
+8.0%
$50.11
$22.28
$59.55
$19.52B1.059.25 million shs3.03 million shs
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
$11.42
-2.5%
$13.55
$11.34
$69.97
$182.11M1.67421,111 shs241,476 shs
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
$7.30
+1.0%
$7.28
$3.71
$11.00
$195.15M1.74579,439 shs334,821 shs
The 7 Hottest IPOs On Wall Street’s 2026 Watchlist Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Metagenomi, Inc. stock logo
MGX
Metagenomi
+1.53%-2.21%-4.32%-16.88%-24.43%
Moderna, Inc. stock logo
MRNA
Moderna
-0.91%-2.96%+0.60%-21.04%+68.72%
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
-4.64%-8.22%-13.82%-16.17%-69.21%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
-4.87%+2.41%-5.74%+2.26%+9.15%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Metagenomi, Inc. stock logo
MGX
Metagenomi
$1.38
+3.4%
$1.38
$1.24
$3.95
$51.73M0.64225,614 shs98,314 shs
Moderna, Inc. stock logo
MRNA
Moderna
$49.28
+8.0%
$50.11
$22.28
$59.55
$19.52B1.059.25 million shs3.03 million shs
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
$11.42
-2.5%
$13.55
$11.34
$69.97
$182.11M1.67421,111 shs241,476 shs
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
$7.30
+1.0%
$7.28
$3.71
$11.00
$195.15M1.74579,439 shs334,821 shs
The 7 Hottest IPOs On Wall Street’s 2026 Watchlist Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Metagenomi, Inc. stock logo
MGX
Metagenomi
+1.53%-2.21%-4.32%-16.88%-24.43%
Moderna, Inc. stock logo
MRNA
Moderna
-0.91%-2.96%+0.60%-21.04%+68.72%
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
-4.64%-8.22%-13.82%-16.17%-69.21%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
-4.87%+2.41%-5.74%+2.26%+9.15%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Metagenomi, Inc. stock logo
MGX
Metagenomi
2.80
Moderate Buy$9.00587.02% Upside
Moderna, Inc. stock logo
MRNA
Moderna
1.83
Reduce$35.73-25.02% Downside
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
2.50
Moderate Buy$22.0093.07% Upside
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
2.67
Moderate Buy$24.75239.97% Upside

Current Analyst Ratings Breakdown

Latest MGX, MRNA, UNCY, and TNXP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2026
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
Reiterated RatingSpeculative Buy$15.00 ➝ $18.00
5/27/2026
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
Reiterated RatingBuy$22.00
5/26/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingNeutral
5/19/2026
Metagenomi, Inc. stock logo
MGX
Metagenomi
DowngradeSell (D-)Sell (E+)
5/13/2026
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
Reiterated RatingBuy$40.00 ➝ $37.00
5/12/2026
Metagenomi, Inc. stock logo
MGX
Metagenomi
Lower Price TargetOverweight$12.00 ➝ $9.00
5/5/2026
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
UpgradeStrong-Buy
5/4/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetNeutral$36.00 ➝ $45.00
5/4/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetSector Perform$35.00 ➝ $38.00
5/4/2026
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
Initiated CoverageBuy$22.00
5/1/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetNeutral$43.00 ➝ $49.00
(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Metagenomi, Inc. stock logo
MGX
Metagenomi
$25.21M1.96N/AN/A$4.22 per share0.31
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B9.73N/AN/A$22.14 per share2.15
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
$17.56M10.35N/AN/A$19.17 per share0.59
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
N/AN/AN/AN/A$1.41 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Metagenomi, Inc. stock logo
MGX
Metagenomi
-$87.87M-$2.30N/AN/AN/A-384.61%-51.23%-36.62%8/11/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%7/31/2026 (Estimated)
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
-$124.02M-$14.36N/AN/AN/A-839.52%-67.65%-60.47%8/10/2026 (Estimated)
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
-$26.56M-$2.21N/A0.90N/AN/A-134.69%-84.51%8/13/2026 (Estimated)

Latest MGX, MRNA, UNCY, and TNXP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2026Q1 2026
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
-$0.4589-$0.54-$0.0811-$0.54$11.11 millionN/A
5/11/2026Q1 2026
Metagenomi, Inc. stock logo
MGX
Metagenomi
-$0.60-$0.61-$0.01-$0.61$5.90 million$1.25 million
5/11/2026Q1 2026
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
-$2.54-$2.93-$0.39-$2.93$6.13 million$6.88 million
5/1/2026Q1 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million
3/30/2026Q4 2025
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
-$0.46-$0.82-$0.36-$0.82$0.52 millionN/A
3/12/2026Q4 2025
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
-$3.16-$3.98-$0.82-$3.98$2.97 million$5.39 million
3/5/2026Q4 2025
Metagenomi, Inc. stock logo
MGX
Metagenomi
-$0.58-$0.60-$0.02-$0.60$7.33 million$3.91 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
N/AN/AN/AN/AN/A
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/A
6.43
6.43
Moderna, Inc. stock logo
MRNA
Moderna
0.08
2.41
2.35
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
N/A
6.99
6.86
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
N/A
2.40
2.40

Institutional Ownership

CompanyInstitutional Ownership
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/A
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
82.26%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
40.42%

Insider Ownership

CompanyInsider Ownership
Metagenomi, Inc. stock logo
MGX
Metagenomi
12.50%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
2.00%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
10.71%
CompanyEmployeesShares OutstandingFree FloatOptionable
Metagenomi, Inc. stock logo
MGX
Metagenomi
23637.65 million32.94 millionN/A
Moderna, Inc. stock logo
MRNA
Moderna
4,700396.79 million353.93 millionOptionable
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
5015.94 million15.62 millionNot Optionable
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
926.70 million23.84 millionNot Optionable

Recent News About These Companies

Unicycive Therapeutics Inc Ordinary Shares UNCY
Unicycive Therapeutics Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Metagenomi stock logo

Metagenomi NASDAQ:MGX

$1.38 +0.05 (+3.38%)
As of 02:30 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Moderna stock logo

Moderna NASDAQ:MRNA

$49.28 +3.64 (+7.98%)
As of 02:30 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Tonix Pharmaceuticals stock logo

Tonix Pharmaceuticals NASDAQ:TNXP

$11.42 -0.30 (-2.53%)
As of 02:30 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Unicycive Therapeutics stock logo

Unicycive Therapeutics NASDAQ:UNCY

$7.30 +0.07 (+0.97%)
As of 02:30 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.